arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Tvardi Therapeutics, Inc.

TVRD
$0.85 ▼ -0.01 (-0.79%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tvardi Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.0M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -62.5% ↘
FCF / Share $-0.98 ↘
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.57M
↑ +20.3% —
Net Income Profit after all expenses
$-6.80M
↑ +29.0% —
Operating Margin Operating profit as % of sales
-92.9%
↑ +60.4% —
FCF / Share Free cash flow per share
$-0.98
↓ -57.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality ↑
76

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 56 quarters